Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psoriasis biomarker profiling and guselkumab response study
NL-OMON52891Phase 4Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of guselkumab in plaque psoriasis and psoriasis (4 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Serum concentration of guselkumab, Anti-guselkumab antibodies and 17 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on NL-OMON52891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52891.